Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.semnephrol.2017.09.008 http://scihub22266oqcxt.onion/10.1016/j.semnephrol.2017.09.008 C5894099!5894099 !29291764     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29291764 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Semin+Nephrol 2018 ; 38 (1 ): 88-97 Nephropedia Template TP {{tp|p=29291764 |t=2018. Translating Knowledge Into Therapy for Acute Kidney Injury |pdf=|usr=}}{{29291764 }} gab.com Text Translating Knowledge Into Therapy for Acute Kidney Injury JO: Semin Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=29291764 #FOAvip No therapies have been shown to improve outcomes in patients with acute kidney injury (AKI). Given the high morbidity and mortality associated with AKI this represents an important unmet medical need. A common feature of all of the therapeutic development efforts for AKI is that none were driven by target selection or preclinical modeling that was based primarily on human data. This is important when considering a heterogeneous and dynamic condition such as AKI, in which in the absence of more accurate molecular classifications, clinical cohorts are likely to include patients with different types of injury at different stages in the injury and repair continuum. The National Institutes of Health precision medicine initiative offers an opportunity to address this. By creating a molecular tissue atlas of AKI, defining patient subgroups, and identifying critical cells and pathways involved in human AKI, this initiative has the potential to transform our current approach to therapeutic discovery. In this review, we discuss the opportunities and challenges that this initiative presents, with a specific focus on AKI, what additional efforts will be needed to apply these discoveries to therapeutic development, and how we believe this effort might lead to the development of new therapeutics for subsets of patients with AKI. Twit Text FOAVip Translating Knowledge Into Therapy for Acute Kidney Injury ????Semin Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=29291764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29291764 #FOAvip English Wikipedia <ref>{{Cite pmid|29291764 }}</ref> Translating Knowledge Into Therapy for Acute Kidney Injury #MMPMID29291764 de Caestecker M ; Harris R Semin Nephrol 2018[Jan]; 38 (1 ): 88-97 PMID29291764 show ga No therapies have been shown to improve outcomes in patients with acute kidney injury (AKI). Given the high morbidity and mortality associated with AKI this represents an important unmet medical need. A common feature of all of the therapeutic development efforts for AKI is that none were driven by target selection or preclinical modeling that was based primarily on human data. This is important when considering a heterogeneous and dynamic condition such as AKI, in which in the absence of more accurate molecular classifications, clinical cohorts are likely to include patients with different types of injury at different stages in the injury and repair continuum. The National Institutes of Health precision medicine initiative offers an opportunity to address this. By creating a molecular tissue atlas of AKI, defining patient subgroups, and identifying critical cells and pathways involved in human AKI, this initiative has the potential to transform our current approach to therapeutic discovery. In this review, we discuss the opportunities and challenges that this initiative presents, with a specific focus on AKI, what additional efforts will be needed to apply these discoveries to therapeutic development, and how we believe this effort might lead to the development of new therapeutics for subsets of patients with AKI. |*Translational Research, Biomedical [MESH] |Acute Kidney Injury/classification/*therapy [MESH] |Biopsy [MESH] |Clinical Trials as Topic [MESH] |Humans [MESH] |Kidney/pathology [MESH] |Patient Selection [MESH] |Phenotype [MESH]Translating Knowledge Into Therapy for Acute Kidney Injury (epmc).pdf DeepDyve Pubget Overpricing